G1 THERAPEUTICS (NASDAQ:GTHX) Director Fredric N. Eshelman acquired 250,000 shares of the company’s stock in a transaction that occurred on Monday, November 13th. The shares were acquired at an average price of $19.73 per share, for a total transaction of $4,932,500.00. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.
Shares of G1 THERAPEUTICS (NASDAQ GTHX) opened at $20.75 on Friday. G1 THERAPEUTICS has a 12 month low of $12.04 and a 12 month high of $28.67.
COPYRIGHT VIOLATION WARNING: This article was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.com-unik.info/2017/11/18/g1-therapeutics-gthx-director-buys-4932500-00-in-stock.html.
Several large investors have recently made changes to their positions in GTHX. American International Group Inc. acquired a new stake in shares of G1 THERAPEUTICS in the third quarter valued at approximately $130,000. California State Teachers Retirement System acquired a new stake in shares of G1 THERAPEUTICS in the third quarter valued at approximately $319,000. Schwab Charles Investment Management Inc. acquired a new stake in shares of G1 THERAPEUTICS in the third quarter valued at approximately $364,000. Alps Advisors Inc. acquired a new stake in shares of G1 THERAPEUTICS in the second quarter valued at approximately $444,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of G1 THERAPEUTICS in the third quarter valued at approximately $568,000. Institutional investors own 35.28% of the company’s stock.
G1 THERAPEUTICS Company Profile
G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.
What are top analysts saying about G1 THERAPEUTICS? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for G1 THERAPEUTICS and related companies.